Nanion Technologies and Nexel Partner to Open a New Reference Demonstration Laboratory in South Korea

摘要

Nanion Technologies and Nexel are pleased to announce a partnership,focused on combining Nanion's CardioExcyte 96 and FLEXcyte 96 cell monitoring technology with Nexel's hiPSC-derived cells for demonstration purposes.Bringing together the two companies'infrastructure and expertise serves to meet the growing demand for a reliable,high throughput cell monitoring technology in Asia.The Nanion-Nexel partnership brings together profound skills in comprehensive in vitro electrophysiology technology and development of human induced pluripotent stem cells(hiPSCs),with focus on cardiomyocytes.Under the partnership,Nexel opens a reference demonstration laboratory for Nanion's systems at Nexel's headquarters in Seoul,whereby both companies aim to significantly upscale support of their clients in Asia.